Our group has previously showed that antibody-based PET nuclear agents, [89Zr]Zr-daratumumab and [89Zr]Zr-elotuzumab targeted to overexpressed proteins CD38 and CS1, respectively, on myeloma cells can be used as companion diagnostics for preclinical imaging of MM [26, 54]. This evidence concerns the gene CD38 and plasma cell myeloma.